-
Product Insights
Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026" provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, 2026" provides an overview of Muscle Invasive Bladder Cancer (MIBC) Clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Invasive Bladder Cancer (MIBC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026" provides an overview of Hemophilia A (Factor VIII Deficiency) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A (Factor VIII Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2026" provides an overview of Social Anxiety Disorder (SAD/Social Phobia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Social Anxiety Disorder (SAD/Social Phobia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trials Review, 2026" provides an overview of Chronic Lymphocytic Leukemia (CLL) Clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Endometriosis - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Endometriosis - Global Clinical Trials Review, 2026" provides an overview of Endometriosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Endometriosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026" provides an overview of Systemic Lupus Erythematosus Clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Lupus Erythematosus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2026" provides an overview of Spondyloarthritis (Spondyloarthropathy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Spondyloarthritis (Spondyloarthropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Thematic Analysis
Asia Beyond China: Pharma R&D and Deal Trends in South Korea, Japan and India: Strategic Intelligence
China continues to lead Asia’s drug development, with other nations following China’s initiatives. Small molecules and oncology remain as the most dominant within Asian drug development markets. South Korea and India expand clinical trial activity while Japan shifts to multinational trials. M&A occurs but remains a secondary channel to licensing across these markets; South Korea and Japan are primarily oriented toward out-licensing innovative assets to US/EU partners.
-
Sector Analysis
Fibromyalgia: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Fibromyalgia Therapeutics._x000D_ _x000D_ • In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of fibromyalgia, representing a large portion of global cases._x000D_ • Currently, the fibromyalgia treatment landscape has a limited number of approved drugs and is saturated with generics._x000D_ • Fibromyalgia’s pipeline is relatively thin, skewed toward Phase I–II investigational assets with no presence of late-stage molecules._x000D_ •...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.